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Abstract With the widespread use of a recently devel-
oped canine influenza virus (CIV) H3N8 vaccine, continual
molecular evaluation of circulating CIVs is necessary for
monitoring antigenic drift. The aim of this project was to
further describe the genetic evolution of CIV, as well as
determine any genetic variation within potential antigenic
regions that might result in antigenic drift. To this end, the
hemagglutinin gene of 19 CIV isolates from dogs residing
in Colorado, New York, and South Carolina humane
shelters was sequenced and compared to CIV strains iso-
lated during 2003–2012. Phylogenetic analysis suggests
that CIV might be diverging into two geographically dis-
tinct lineages. Using a mixed-effects model for evolution
and single likelihood ancestor counting methods, several
amino acid sites were found to be undergoing selection
pressure. Additionally, a total of six amino acid changes
were observed in two possible antigenic sites for CIVs
isolated from Colorado and New York humane shelters
between 2009 and 2011. As CIV isolates might be
diverging into geographically distinct lineages, further
experiments are warranted to determine the extent of
antigenic drift occurring within circulating CIV.
Keywords Influenza A virus  MEME analysis 
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Introduction
Although serological evidence suggests H3N8 canine
influenza virus (CIV) has been circulating in U.S. dogs
since as early as 1999 [1], it was not until 2004 that the
virus was isolated from Florida racing greyhounds exhib-
iting signs of infectious respiratory disease [2]. Early
phylogenetic analyses showed CIV, an influenza A virus in
the family Orthomyxoviridae, to be closely related to
contemporary equine influenza viruses (EIV) of the Florida
Clade 1 sublineage [2, 3]. From the emerging CIVs, ten
amino acid substitutions within the hemagglutinin (HA),
neuraminidase, nucleoprotein, and polymerase proteins
were identified [3]. Unlike other horse-to-dog EIV trans-
mission events in which dogs have been only incidentally
infected [4, 5], CIV represents a new threat to canine
health, as the virus rapidly spreads to naı¨ve dogs
throughout the racing track circuit [2, 6], animal shelters
[2, 7, 8], and boarding facilities [9]. Despite successful
experimental transmission of EIV and CIV in both horses
and dogs [10–13], host restriction is currently being
maintained in naturally-infected animals [14]. Further-
more, CIV isolates sequenced between 2005 and 2008
share the same ten amino acid substitutions originally
identified in early Florida CIV, as well as an additional
nine amino acid substitutions among the influenza proteins
[14] (three within the HA alone). These findings indicate
that CIV continues to evolve from both its canine and
equine influenza predecessors.
Given its vital role during influenza infection, it is not
surprising that the HA protein of influenza A virus is the
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main target for antibody attachment and virus neutraliza-
tion [15, 16]. Five antigenic regions (A–E) have been
identified in the HA subtype 3 (H3) HA1 subunit protein of
human and equine influenza viruses [17–21], and mutations
within these antigenic regions have been associated with
immune escape or antigenic drift [22], which can result in
vaccine failure and increased host susceptibility to influ-
enza infection. It has been suggested that antigenic drift has
epidemiological impact when four or more amino acid
substitutions are located within at least two of these anti-
genic regions [22]. Antigenic drift has been reported in
human H3 influenza viruses [19, 21], with influenza strains
clustering into antigenic groups over time. For example,
influenza A H3N2 viruses isolated from humans between
1968 and 2003 formed 11 distinct antigenic clusters [21].
Equine influenza viruses, in contrast, clustered into only
three antigenic groups over the same time period [23],
while antigenic drift has yet to be detected or described in
CIVs isolated from dogs [24, 25].
With the widespread use of a recently developed killed
CIV vaccine [26], continual molecular evaluation of circu-
lating CIVs is clearly necessary for monitoring antigenic
drift. Furthermore, as CIV emerged only within the last
decade, it is important to continually monitor its genetic
diversity and whether geographically distinct viral lineages
are evolving [2, 3, 14, 27]. By analyzing the HA nucleotide
and protein sequences of the published set of CIVs, as well as
the newly isolated CIVs from CIV-epidemic and -endemic
U.S. regions, we are able to further describe the evolution of
CIV since it first emerged in 2004, and report amino acid
variations within potential antigenic sites that could possibly
result in the first clustering of antigenically distinct CIVs.
Materials and methods
Animals
Dogs residing in six U.S. shelters participated in this
prospective study. The six shelters were located near or
within metropolitan centers (Sacramento, CA; Colorado
Springs, CO; Tampa Bay, FL; New York, NY; Charles-
town, SC; and Austin, TX) and were part of a larger CIV
surveillance study conducted from December 2009 to
January 2012 [28]. Shelters were chosen in regions that
were considered CIV-endemic (CO, FL, NY), where pre-
vious studies have reported CIV outbreaks [2, 6, 27, 28],
and in regions where CIV status was unknown (CA, SC,
TX). Nasal swabs were taken from approximately 40 dogs
every month per shelter, and all dogs, irrespective of age,
breed, sex, and vaccination or health status, were consid-
ered eligible to participate. Prior to initiation, all studies
were reviewed and approved by Colorado State University
IACUC.
Clinical samples
Nasal swab samples were collected from dogs on-site at
each humane shelter, as previously described [8, 28].
Samples were refrigerated at 4 C and shipped monthly to
Colorado State University Veterinary Teaching Hospital
(VTH). Upon arrival in the laboratory, 200 ll of nasal
swab viral transport medium was removed from each
sample and placed in a 96-well block for later ribonucleic
acid (RNA) isolation. The remaining sample, along with
the samples in the 96-well block, were immediately stored
at -80 C until further processing.
Real-time reverse transcription-polymerase chain
reaction (RT-PCR) assay
Using an automated RNA isolation system (Qiagen Qiax-
tractor; Hilden, Germany), viral RNA was extracted from
the 200-ll viral transport medium aliquots and eluted in a
final volume of 60 ll water. A one-step real-time RT-PCR
assay developed by members of or laboratory was per-
formed to identify any CIV-positive clinical samples, as
previously described [8]. Briefly, a 5-ll aliquot of RNA
template was mixed with 20 ll of mixture containing
iScript One-Step RT-PCR Kit reagents (BioRad; Hercules,
CA), 80 nmol of probe, and 200 nmol of forward (50 GAA
CAC CGA TCT TGA GGC ACT C 30) and 200 nmol of
reverse (50 GGC ATT TTG GAC AAA GCG TCT AC 30)
primers to amplify 144 bp of the conserved influenza A
virus matrix gene. Water and viral transport medium were
used as negative controls, while the positive control con-
sisted of 10 TCID50 of A/canine/CO/224986/2006
(H3N8). An epMotion Ep5070p (Eppendorf; Hamburg,
Germany) automated system was used to load 96-well
plates before amplification and detection by Mastercycler
Realplex (Eppendorf), using previously described condi-
tions [8].
Virus isolation
All real-time RT-PCR CIV-positive nasal swabs were
stored at -80 C until virus isolation could be performed.
Aliquots of 150–200 ll thawed viral transport medium
were injected under the illumination of an electronic egg
candle into the allantoic cavities of three 10-day old
embryonated hen eggs. In addition, 50 ll of nasal swab
sample was inoculated into MDCK cells on 6-well plates in
duplicate. Inoculation medium contained both antibiotic
(gentamicin for the egg inoculation and penicillin and
streptomycin for the cell culture inoculations) and
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antifungal (amphotericin B) agents, as previously described
[8]. Each isolate was blind-passaged twice (for a total of
three passages) using 200 ll of the previous passage and
evaluated for CIV by hemagglutination inhibition (HI)
assays. All first-passaged and HI-positive isolates were
additionally tested for the presence of the influenza matrix
gene by real-time RT-PCR.
Sequencing
The full-length HA protein-coding region for each isolated
virus was amplified by a two-step RT-PCR. Briefly, extrac-
ted viral RNA was reverse transcribed using SZAHA primers
[29] and SuperScriptTM III reverse transcriptase (Gibco/
Invitrogen, Carlsbad, CA) before HA cDNAs were amplified
by PCR using Platinum Taq DNA polymerase high fidelity
(Gibco/Invitrogen). PCR products were obtained by direct
cycle sequencing using ABI Big Dye (PE Applied Biosys-
tems, Foster City, CA) and sequenced at the Proteomics and
Metabolomics Facility at CSU (http://www.dnatools.com).
Nucleotide sequences of RNA from the shelter dog study, as
well as several Colorado and Wyoming CIVs isolated in our
laboratory since 2006, were compiled de novo using Gene-
ious Pro software [30] and deposited into GenBank under
accession numbers JX235372 through JX235394.
Evolutionary and antigenic analyses
Both nucleotide and amino acid alignments were assem-
bled using the Kyoto University Bioinformatics Center’s
multiple sequence alignment online tool (http://www.gen
ome.jp/tools/clustalw/). All available H3N8 CIV full-
length HA sequences published up until 25-Jun-2012 were
downloaded from the Influenza Virus Resource, National
Center for Biotechnology Information (NCBI) database.
Additionally, HAs of viruses previously sequenced by
members of our laboratory (GenBank accession numbers
HQ917678–HQ917681) were included. In total, there were
62 sequences (19 new shelter, 9 Colorado and Wyoming
strains previously isolated by members of our laboratory,
and 34 published sequences). Potential antigenic regions
were identified according to sites reported for human and
equine influenza H3 viruses [17–21]. The phylogenetic tree
was inferred by amino acid analysis based on maximum
parsimony with 1,000 bootstrap repeats and rooted to EIV
Pre-divergence strains using MEGA5 [31]. To determine
selection pressure, the Datamonkey web server [32, 33]
using the HyPhy software package [34] was utilized to
evaluate the nucleotide sequences from 58 (17 shelter, 8
previously sequenced in our laboratory, and 33 published)
isolates; four nucleotide sequences were identical to other
isolates and were excluded from analysis. Because more
than two mutations might segregate at a single site in viral
populations [35], the mixed-effects model for evolution
(MEME) [36] method was used, using the HKY85 nucle-
otide substitution bias model. This method accounts for
episodic selection at each individual amino acid site, rather
than at only the node or branch alone [36]. Additionally, to
account for any false positives in the MEME method, the
single likelihood ancestor counting method [37] was also
used to confirm any sites found to be undergoing selection
pressure by the MEME analysis.
Results
Virus isolation
Over 5,100 nasal swab samples were collected from shelter
dogs entering and exiting the six participating humane
shelters over the study period. Of these, 111 were positive
upon real-time RT-PCR for the influenza matrix gene
(Table 1). After three passages in both embryonated hen
eggs and MDCK cells, 19 viruses (17 %) were isolated
and their HA genes were sequenced. The majority of these
(11/19) were grown in allantoic fluid only, while one was
grown in cell culture only, and seven viruses grew in both
culture systems. Most of the isolates were from the Colo-
rado and New York shelters, although one virus each was
isolated from the Florida and South Carolina shelters.
Interestingly, all of the Colorado isolates were obtained in
the first year of the study (2009–2010), while all of the
New York viruses were from nasal swabs collected during
study year two (2010–2011) (Table 2). Additionally, the
South Carolina virus was collected during the CIV-out-
break that occurred in a South Carolina shelter during the
first month of the study (December 2009). The other
viruses listed in Table 2 were isolated from either pet dogs
seen at the Colorado State University Veterinary Teaching
Hospital or were collected from dogs residing at Colorado
and Wyoming humane shelters during reported outbreaks
of canine infectious respiratory disease from 2006 to 2007.
Table 1 Viruses isolated from dogs residing in humane shelters







California 854 1 0
Colorado 1037 38 7
Florida 953 12 0
New York 863 37 11
South Carolina 708 23 1
Texas 771 0 0
TOTAL 5186 111 19
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Genetic evolution of CIV
Genetic analysis of HA amino acid sequences suggests
that recent CIVs appear to have evolved from earlier
CIVs, as they have consistently maintained the originally
described HA mutations from A/Ca/Florida/03 and A/Ca/
Florida/04 [2, 3]. Additionally, phylogenetic analysis
further suggests that CIV may be diverging regionally
(Fig. 1), with the New York/South Carolina and the
Colorado CIV isolates clustering separately from one
another. Although viruses from these two regions share
eight of the original nine adaptations from EIV and
emerging CIV identified by Payungporn et al. [3], as well
as the three HA substitutions reported by Rivallier et al.
[14], there were an additional 12 amino acid differences
among Colorado and New York CIV isolates (I58V,
H75Q, D/E77D, I112V, G/E124G, K172K/E, Y174F,
V223I, T/I242I, M268I, G/D464N/D, and L496I). Inter-
estingly, six of these twelve newly identified differences
were within H3 antigenic regions (Table 3). Moreover,
nine amino acid differences appear among the viruses
isolated during early infections in Colorado and Wyoming
(2006–2007) and the isolates collected during the shelter
study (2009–2010): D/E77E, S/L107L, V112I, G/E124G,
F174Y, G/R218G, T/I242I, G/D464D, and E479K. This
last site is of particular interest as it was one of the CIV
substitutions identified when CIV was first detected in
2004 [2, 3].
The MEME analysis revealed five sites exhibiting evi-
dence of episodic diversifying selection at a significance
level of p \ 0.1. These included H3 amino acid residues
107, 169, 216, 453, and 464. Site 107 has been reported to
be involved in cellular immunity [38], while sites 169 and
216 are located in or near potential antigenic sites. Amino
acid residues 453 and 464 are located on the highly con-
served HA2 subunit of the HA protein. However, the single
likelihood ancestor counting method only shared amino
acid residue 464 as undergoing positive selection pressure,
while residues 184, 449, 458, and 506 were considered
undergoing negative selection pressure.
Table 2 Canine influenza
viruses isolated from nasal
swabs collected from dogs
during 2006–2011
a Passage used for sequencing,
either from cell culture (C) or
embryonated hen eggs (E).
Number following C or E
indicates number of passages.
When isolates were sequenced
from both embryonated hen
eggs and cell culture, the
sequences were found to be
identical
b Colorado State University
Veterinary Teaching Hospital
Strain Date collected Passagea Location
A/canine/CO/224986/2006 06-Jun-06 C3 CSU VTHb
A/canine/CO/148902/2006 30-Oct-06 C2 Humane shelter
A/canine/CO/3/2006 28-Apr-06 C3 CSU VTH
A/canine/CO/224766/2006 24-May-06 C2 CSU VTH
A/canine/WY/86033/2007 14-Feb-07 E3; C3 Humane shelter
A/canine/CO/231256/2007 08-Mar-07 C6 Humane shelter
A/canine/WY/86955/2007 27-Feb-07 E1; C3 Humane shelter
A/canine/CO/2025974/2007 14-Mar-07 E1; C3 Humane shelter
A/canine/CO/234550/2009 27-Feb-09 C6 CSU VTH
A/canine/SC/89215/2009 05-Dec-09 E3 Humane shelter
A/canine/CO/850078/2009 31-Dec-09 E3 Humane shelter
A/canine/CO/861142/2010 03-Mar-10 E3 Humane shelter
A/canine/CO/861997/2010 09-Mar-10 E3 Humane shelter
A/canine/CO/863160/2010 20-Mar-10 E3 Humane shelter
A/canine/CO/866907/2010 10-Apr-10 E3 Humane shelter
A/canine/CO/884753/2010 21-Jul-10 C1 Humane shelter
A/canine/CO/886050/2010 27-Jul-10 C3 Humane shelter
A/canine/NY/6977983/2010 05-Sep-10 E3 Humane shelter
A/canine/NY/12370090/2011 12-Feb-11 E4 Humane shelter
A/canine/NY/13258337/2011 05-Jun-11 E3 Humane shelter
A/canine/NY/13454104/2011 30-Jun-11 E1 Humane shelter
A/canine/NY/13453967/2011 30-Jun-11 C1 Humane shelter
A/canine/NY/3821631/2011 06-Jul-11 E3 Humane shelter
A/canine/NY/13693247/2011 03-Aug-11 E1 Humane shelter
A/canine/NY/13752393/2011 12-Aug-11 E3 Humane shelter
A/canine/NY/13889381/2011 25-Aug-11 E3 Humane shelter
A/canine/NY/13949315/2011 01-Sep-11 E1 Humane shelter
A/canine/NY/13949306/2011 01-Sep-11 E2 Humane shelter
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Discussion
Since the emergence of CIV nearly 10 years ago, the virus
has circulated in a number of dog populations, most
notably in dogs residing in humane shelters [2, 7]. Indeed,
CIV is routinely isolated from such facilities [8, 14, 27].
Whether this is because there are actually more CIV
infections in shelter dogs compared to non-shelter dogs or
there is more surveillance in this particular population is a
matter under current study [28]. Nevertheless, the frequent
isolation of CIVs in shelter dogs presents a unique
opportunity to characterize genetic evolution and antigenic
variation of a relatively novel influenza A virus ‘‘in situ.’’
Results from these studies and others [14, 27] suggest
that CIV might be diverging into two regionally distinct
lineages: Colorado and New York. Indeed, the recent New
York viruses and the one South Carolina isolate appear to
cluster separately from CIVs isolated in Colorado and
Wyoming (Fig. 1). Additionally, a number of CIV lineages
have not been isolated recently. For example, isolates from
a Wyoming animal shelter (A/canine/WY/86955/2007 and
A/canine/WY/86033/2007) are not clustered with any of
the newer Colorado isolates (Fig. 1), while, instead, recent
Colorado CIVs are clustered with viruses isolated from
dogs residing at other animal shelters located within Col-
orado. Despite the possible geographical divergence of
Fig. 1 Phylogenetic
comparison of canine and
equine influenza virus H3 genes.
Amino acid analysis was based
on maximum parsimony with
bootstrap analysis (values with
[50 % consensus shown) and
rooted to the EIV Pre-
divergence strains
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CIV, the separate lineages might be due rather to temporal
mutations, as the Colorado CIVs were isolated in 2009 and
2010, before the New York CIVs were isolated in 2010 and
2011. However, giving more weight to the regional
divergence claim is the fact that the South Carolina CIV,
which most resembles the New York CIVs, was isolated in
2009, before the Colorado CIVs were isolated.
The MEME analysis found five sites in the HA coding
region undergoing episodic diversifying selection: 107,
169, 216, 453, and 464. Three of these sites (AA residues
107, 169, and 216) are located on the HA1 protein (HA sites
1 through 328), including one site located in an potential
antigenic region, while two of these (residues 453 and 464)
are on the HA2 protein (residues 330 through 550). The
single likelihood ancestor counting method also identified
464 as undergoing positive selection pressure, suggesting
that there are indeed amino acid changes occurring within
the highly conserved HA2 protein. Although residue 107
was not identified by single likelihood ancestor counting
analysis as undergoing selection pressure, substitutions at
site 107 were reported in 2008 as a replacement of serine in
the conserved EIV and early Florida CIV isolates by a
proline in the A/canine/Jacksonville/2005 strain [3]. Site
107 appears to be part of a peptide region (AA residues
105-140) that might stimulate proliferation of T helper cells
[38]. Isolates substituting serine at position 107 change the
amino acid from one with a polar uncharged side chain to
either one with a secondary amine (proline) or one with a
hydrophobic side chain (leucine). However, recent isolates
from both New York and Colorado show a leucine substi-
tution at this site instead.
With eight amino acid substitutions within three potential
antigenic regions, antigenic drift might also be occurring for
the newer CIV isolates. However, it is important to note that
E124 (site A) was only observed in two of the viruses isolated
after the Wyoming 2006 outbreak (A/canine/CO/231256/
2007 and A/canine/WY/86033/2007). Other mutations seen
in only a few isolates included two clinical samples from the
Colorado State University Veterinary Teaching Hospital with
I242T (A/canine/CO/3/2006 and A/canine/CO/224766/2006)
and two shelter CIVs with K172E (A/canine/SC/89215/2009
and A/canine/NY/13693247/2011). Despite these transient
mutations, it appears that five consistent substitutions have
occurred in the Colorado and New York isolates. In antigenic
site D, two amino acid substitutions (N216H and V223I) were
identified in the New York isolates. Also within site D, another
substitution (F174Y) was seen in the CIVs isolated from the
Colorado shelter during 2009–2010, while within antigenic
site E, two amino acid residue mutations were seen in New
York isolates (H75Q and P262T).
These consistent mutations among CIV isolates, despite
passage number and culture system, suggest that CIV is
indeed evolving and not an artificial result of in vitro selec-
tion pressure. Additionally, as the analyses presented here
are based on genomic and antigenic sites described for
human and equine H3 influenza A viruses [17–21], it is
possible that the CIV HA has different antigenic regions that
have yet to be defined. More research on CIV is warranted to
confirm the structure of the CIV HA protein, map antigenic
regions associated with virus neutralization and antigenic
drift, and further investigate antigenic variation leading to
CIV immune escape. Finally, one limitation of our study was
the possible degradation of nasal swab samples between
collection, transport, and processing, as well as the fact that
sequencing directly from nasal swabs has, thus, far been
unsuccessful. As samples were stored on-site at humane
shelters before being shipped to the Colorado State Univer-
sity laboratory, infectious virus might have been compro-
mised, which could account for our low number of isolates.
Future studies utilizing virus isolation might want to find a
quicker, yet practical, protocol for sending samples to the
laboratory soon after collection.
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